

# DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C VIRUS IN HIV CO-INFECTED PATIENTS

Contreras Rey MB, Estaire Gutiérrez J, Sánchez del Moral R, Romero Alonso MM, Bolívar Raya MA, <sup>2</sup>Bocanegra Martín C

Infanta Elena Hospital. <sup>2</sup>Juan Ramón Jiménez Hospital. Pharmacy. Huelva, Spain

5PSQ-046

J05 Antivirals for systemic use



## BACKGROUND

The development of new direct acting antivirals (DAAs) for hepatitis C virus (HCV) represents an evolution in the treatment.

As HIV-HCV coinfection is common, evaluation of DAAs effectiveness and drug interactions with antiretroviral therapy (ART) is useful in this population.

## OBJECTIVES



To assess the effectiveness of DAAs and drug interactions with ART in HIV/HCV-coinfected patients.

## METHODS

- Retrospective observational study, including HIV/HCV-coinfected patients who started DAAs (August 2015 - August 2017).
- Data were obtained from outpatient software, electronic health records or interview with patients.
- Effectiveness was assessed by achievement of virological response (week 4 of treatment, end of treatment and post-treatment week 12).
- Interactions between DAAs and ART were evaluated by using University of Liverpool Drug Interaction database.

## RESULTS

- 66 HIV/HCV-coinfected patients (21.2% women), mean age 50.1 years (40-57; SD 3.9).
- HCV genotype distribution: 1a (40.9%), 4 (22.7%), 3 (18.2%), 1b (16.7%) and 2 (1.5%).
- 37.9% had cirrhosis and 15.2% were pretreated HCV patients.
- Median baseline HCV viral load was 1 942 570 IU/mL.



39 potential interactions and 5 contraindications between DAAs and ART were identified, mostly only required monitoring.

Prescription of DAAs supposed: modifications in ART (12 cases) and a dose adjustment for the DAA (1 case )

Analysis date: 58 patients had finished treatment, 3 were still receiving DAAs and 5 had discontinued it.

- 63.6% had a rapid virological response (**week 4 of treatment**).
- In patients who completed DAA regimens: 92.1% had undetectable viral load at the **end of treatment**.
- Of 54 patients who reached **post-treatment week 12**: 50 had sustained virological response, 2 presented detectable viral load (resistance mutations were found) and 2 had missed data.

## CONCLUSIONS

DAAs have shown a high effectiveness in HIV/HCV co-infected patients. In this population, it's essential an appropriate revision and management of drug interactions with ART.